RASSF1-1 Variant C: A Potential Drug Target Or Biomarker (G11186)

Target Name: RASSF1

NCBI ID: G11186

RASSF1

RASSF1-1 Variant C: A Potential Drug Target Or Biomarker

The RASSF1 gene is a member of the RASSF gene family, which is involved in the regulation of cell adhesion, migration, and invasion. RASSF1 variants have been found to be involved in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The focus of this article is RASSF1 variant C, which is a potential drug target or biomarker.

Expression and function of RASSF1

RASSF1 is a 21-kDa protein that is expressed in various tissues and cells, including neural, muscle, and epithelial cells. It is involved in the regulation of cell adhesion, migration, and invasion, and its expression is often associated with the execution of these processes. RASSF1 is a member of the RASSF gene family, which is characterized by the presence of a specific domain called the RASSF1-1 domain. This domain is responsible for the interaction of RASSF1 with various signaling pathways, including the TGF-β pathway.

RASSF1-1 domain

The RASSF1-1 domain is a 100 amino acid long protein that is located at the N-terminus of the RASSF1 protein. It is involved in the regulation of cell adhesion, migration, and invasion, and is thought to play a key role in these processes. The RASSF1-1 domain contains several unique features that are involved in its function, including the presence of a helix that is involved in the formation of a complex with the TGF-β receptor. This interaction between RASSF1-1 and TGF-β is thought to be involved in the regulation of cell growth, differentiation, and survival.

In addition to its involvement in the TGF-β pathway, the RASSF1-1 domain is also involved in the regulation of various signaling pathways, including the PI3K/Akt pathway and the NF-kappa-B pathway. These signaling pathways are involved in the regulation of cell adhesion, migration, and invasion, and are thought to be involved in the development and progression of various diseases, including cancer.

Drug targeting and biomarker potential

The potential drug targeting of RASSF1-1 variant C is due to its involvement in the TGF-β pathway and its regulation of cell adhesion, migration, and invasion. Drugs that are currently being developed to target RASSF1-1 variant C include inhibitors of the TGF-β receptor, such as tyrantidine and gefitenam, as well as inhibitors of the PI3K/Akt pathway, such as U0126 and LY294000. These drugs have been shown to have therapeutic effects in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, RASSF1-1 variant C may also be used as a biomarker for various diseases. Its involvement in the TGF-β pathway and its regulation of cell adhesion, migration, and invasion make it an attractive candidate for use as a biomarker for various diseases, including cancer. The expression of RASSF1-1 variant C has been shown to be increased in various diseases, including cancer, and may be used as a diagnostic marker for these diseases.

Conclusion

RASSF1 variant C is a member of the RASSF gene family that is involved in the regulation of cell adhesion, migration, and invasion. Its expression and function have been studied extensively, and its potential as a drug target or biomarker for various diseases have been identified. Further research is needed to fully understand the role of RASSF1-1 variant C in the development and progression of various diseases, including cancer.

Protein Name: Ras Association Domain Family Member 1

Functions: Potential tumor suppressor. Required for death receptor-dependent apoptosis. Mediates activation of STK3/MST2 and STK4/MST1 during Fas-induced apoptosis by preventing their dephosphorylation. When associated with MOAP1, promotes BAX conformational change and translocation to mitochondrial membranes in response to TNF and TNFSF10 stimulation. Isoform A interacts with CDC20, an activator of the anaphase-promoting complex, APC, resulting in the inhibition of APC activity and mitotic progression. Inhibits proliferation by negatively regulating cell cycle progression at the level of G1/S-phase transition by regulating accumulation of cyclin D1 protein. Isoform C has been shown not to perform these roles, no function has been identified for this isoform. Isoform A disrupts interactions among MDM2, DAXX and USP7, thus contributing to the efficient activation of TP53 by promoting MDM2 self-ubiquitination in cell-cycle checkpoint control in response to DNA damage

The "RASSF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RASSF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets